Healthcare >> CEO Interviews >> June 4, 2004
KEITH O. ELLISTON, PhD - President and CEO of Genstruct. Dr. Elliston is
an experienced entrepreneur and intrapreneur who has dedicated his
career to the development and application of leading-edge technology
into the drug discovery process. Dr. Elliston spent over 10 years with
the Merck Research Laboratories, where he led the integration of
molecular sequencing technologies into discovery research, the
development of computational molecular biology and bioinformatics, and
pioneered the application of genomics and molecular profiling. Dr.
Elliston served as the Director of Bioinformatics, and the Scientific
Director of the Merck Gene Index project. From Merck, Dr. Elliston
joined Bayer Pharmaceuticals where he founded their global genomics and
bioinformatics efforts, and was the Section Head of Genomics and the
World Wide Head of Bioinformatics. In 1997 he joined Gene Logic as the
Sr. VP of Research and Development and Chief Scientific Officer. At Gene
Logic, Dr. Elliston pioneered the development and application of
molecular profiling to drug discovery, and was responsible for the
development and management of 6 pharmaceutical research partnerships
representing over $350M in potential revenues to the company. In 1999,
Dr. Elliston founded Viaken Systems, where he was Chairman, President
and CEO. Keith has been an advisor to Oak Investment Partners, Atlas
Ventures and other biotechnology venture capital groups, and has
participated in the early stage development of a number of biotech
companies, including Sequana Therapeutics, Structural Genomics and
Spotfire. Keith received an M.S. in Genetics from the University of
Minnesota, and a Ph.D. in Molecular Genetics from Rutgers University. Profile
including the company's history, products, services, and core markets?
Dr. Elliston: Genstruct is a mechanism discovery
